Free Trial

Arbutus Biopharma (ABUS) News Today

$3.29
+0.01 (+0.30%)
(As of 05/24/2024 04:00 PM ET)
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 4.7%
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.29
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $3.29
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%
Arbutus Biopharma Corp ABUS
Arbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.
Arbutus: Q1 Earnings Snapshot
Arbutus Biopharma earnings: here's what to expect
Arbutus Biopharma Corp
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase
Arbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP Securities
JMP Securities reiterated a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.
Arbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.25
ABUS Jan 2025 7.000 call
Hudson Bay Capital Management LP Purchases 1,302,978 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
Hudson Bay Capital Management LP lifted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 45.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,149,904 shares of the bioph
Arbutus Biopharma Target of Unusually Large Options Trading (NASDAQ:ABUS)
Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 31,568 call options on the stock. This represents an increase of 2,744% compared to the typical daily volume of 1,110 call options.
FY2024 EPS Estimates for Arbutus Biopharma Co. Raised by Chardan Capital (NASDAQ:ABUS)
Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Equities research analysts at Chardan Capital upped their FY2024 EPS estimates for Arbutus Biopharma in a research note issued on Sunday, March 3rd. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Meets Estimates
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative net margin of 339.32% and a negative return on equity of 56.45%. During the same period last year, the firm earned ($0.14) earnings per share.
Arbutus Biopharma (NASDAQ:ABUS) Given New $5.00 Price Target at HC Wainwright
HC Wainwright reduced their price objective on Arbutus Biopharma from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday.
Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)

Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls.

Claim your free seat by clicking here now.

ABUS Media Mentions By Week

ABUS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABUS
News Sentiment

0.71

0.88

Average
Medical
News Sentiment

ABUS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABUS Articles
This Week

9

2

ABUS Articles
Average Week

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ABUS) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners